Please login to the form below

Not currently logged in
Email:
Password:

pipelines

This page shows the latest pipelines news and features for those working in and with pharma, biotech and healthcare.

AZ says dropping MedImmune will help ‘streamline’ its R&D

AZ says dropping MedImmune will help ‘streamline’ its R&D

Will also drop other candidates that haven’t hit the mark. The demise of the MedImmune brand, which has driven AstraZeneca’s biologics pipeline for more than a decade, will strengthen ... He insisted that in reality “the reorganisation doesn't

Latest news

More from news
Approximately 14 fully matching, plus 1,612 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Analysts predict the drug could make up to $2bn in peak sales, making it one of the brightest prospects in Shire’s pipeline.

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    2. The pipeline is booming:Drug approvals are on a steady increase globally. ... 3. The science is increasingly more complex:Many of the highest-potential innovations in the pipeline answer unmet needs in largely elusive disease states.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    A study published earlier this year found that the proportion of pipeline molecules at the unit that moved from preclinical investigation to completion of phase 3 trials rose from 4% to ... She has truly had a significant impact on transforming

  • Deal Watch October 2018

    Acquisition. $2B. Tango Therapeutics/. Gilead Sciences. Pipeline of up to 5 targeted immuno‐oncology. ... Finally, following a full pipeline review, Novartis has reduced its drug programmes from 430 to 340, leaving 90 products adrift, many of which may

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Focusing on pipeline products is no longer enough to assess the regulatory risks posed by a transaction.

More from intelligence
Approximately 1 fully matching, plus 132 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 177 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 39 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics